Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 6/20 | 0.42 |
| ▸ | RAF1 | P04049 | 5/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 8/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12377502 | 0.83 | DYRK1A (0.54) | DYRK1ARAF1METMAPK14MAPK13 | |
| SCHEMBL2285129 | 0.81 | MET (0.63) | DYRK1ARAF1TSHRMEN1KMT2A | |
| SCHEMBL12377529 | 0.81 | NSD3 (0.43) | DYRK1ARAF1MEN1KMT2AMET | |
| SCHEMBL12377494 | 0.78 | RAF1 (0.63) | DYRK1ARAF1METMAPK14MAPK13 | |
| SCHEMBL12377492 | 0.76 | MET (0.47) | DYRK1ARAF1METMAPK14MAPK13 | |
| SCHEMBL12377508 | 0.76 | MET (0.63) | DYRK1ARAF1METMAPK14MAPK13 | |
| SCHEMBL12377503 | 0.76 | MET (0.63) | DYRK1ARAF1METMAPK14MAPK13 | |
| SCHEMBL12377497 | 0.76 | DYRK1A (0.49) | DYRK1ARAF1METMAPK14MAPK13 | |
| SCHEMBL12377501 | 0.74 | DYRK1A (0.44) | DYRK1ARAF1METMAPK14MAPK13 | |
| SCHEMBL12377518 | 0.74 | MET (0.53) | DYRK1ARAF1METMAPK14MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207732-A1 | AZAINDOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207732-A1 | AZAINDOLE DERIVATIVES | AZI2, ABL1, RET | DYRK1A 153/4885RAF1 281/4885TSHR 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.